JPRN-jRCT2080220407未知3 期
A Double-Blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast Cancer
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Female
入选标准
- •Genders Eligible for Study: Female
- •Inclusion Criteria:
- •Biopsy confirmation of breast cancer. Evidence of breast cancer that is not considered amenable to curative treatment.
- •Postmenopausal women. Written informed consent to participate in the study.
排除标准
- •Previous treatment with hormonal therapy unless that therapy was tamoxifen for adjuvant breast cancer. The use of tamoxifen must have ceased at least one year before this study.
- •Previous treatment with Faslodex. Any existing serious disease, illness, or condition that will prevent participation or compliance with the study procedures.
- •Treatment with an investigational or non-approved drug within one month of then start of the study.
研究者
相似试验
进行中（未招募）
1 期
A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) recipients with bronchiolitis obliterans syndrome (BOS) grade 1-2Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation.MedDRA version: 20.0 Level: PT Classification code 10029888 Term: Obliterative bronchiolitis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-001747-31-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)80
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced Non CCR5-Tropic HIV-1 Infected SubjectEUCTR2004-001779-20-ITPfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 582192
已完成
2 期
The survival and quality of life benefits of melatonin when administered to cancer patients at the optimal time of dayThe affects of adjuvant melatonin on the outcomes of stage III and IV non small cell lung cancer patientsCancerISRCTN16419921Cancer Treatment Centers of America®90
已完成
3 期
A phase III study of ONO-4538(ONO-4538-52/TASUKI-52)JPRN-jRCT2080223505ONO PHARMACEUTICAL CO.,LTD.530
招募中
不适用
Double-blind Randomized Multi-center Trial Regarding the Effects of Solution for Gemcitabine on Frequency and Degree of Vascular Pain in Patients with CancerJPRN-UMIN000001827Tohoku University Translational Research Center90